Boaz Weinstein’s Humacyte HUMA Stock Holding History

Boaz Weinstein’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-55,100	Closed	-$553K	–	447
2020 Q4	$553K	Buy	+55,100	New	+$546K	0.02%	132

Other funds holding HUMA

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.1B AUM 13.6% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Boaz Weinstein's HUMA Position: Q1 2021 in Review

Boaz Weinstein sold out of Humacyte (HUMA) in Q1 2021, closing a stake of 55,100 shares — an estimated $553K sold.

Boaz Weinstein first reported a position in HUMA in Q4 2020 and held it in 1 quarter. The position peaked at $553K in Q4 2020. 23 funds tracked by Wall St. Rank hold HUMA as of Q1 2021.

Boaz Weinstein reported no remaining Humacyte position as of Q1 2021 after selling out during the quarter.
Boaz Weinstein sold 55,100 Humacyte shares in Q1 2021, an estimated $553K.
Boaz Weinstein first reported a position in Humacyte in Q4 2020 and held it in 1 quarter.
Boaz Weinstein's Humacyte position peaked at $553K in Q4 2020.
23 funds tracked by Wall St. Rank held Humacyte as of Q1 2021.

Based on Saba Capital Management's 13F filing for Q1 2021, filed 17 May 2021.